Patents by Inventor Joseph Eckenrode

Joseph Eckenrode has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11692003
    Abstract: Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 4, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • Publication number: 20220033429
    Abstract: Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.
    Type: Application
    Filed: September 20, 2019
    Publication date: February 3, 2022
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • Patent number: 11224609
    Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 18, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal
  • Publication number: 20190083519
    Abstract: Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 21, 2019
    Inventors: Jurgen Rohr, Oleg Tsodikov, Markos Leggas, Caixia Hou, Joseph Eckenrode, Prithiba Mitra, Abhisek Mandal